GlaxoSmithKline Pharmaceuticals Limited Total Liabilities
GlaxoSmithKline Pharmaceuticals Limited total liabilities. Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has total liabilities worth Rs19.57 Billion INR (≈ $211.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GlaxoSmithKline Pharmaceuticals Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
Total liabilities of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore GLAXO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
GlaxoSmithKline Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥5.04 Billion |
|
Meritage Corporation
NYSE:MTH
|
USA | $2.47 Billion |
|
Shanghai Electric Power Co Ltd
SHG:600021
|
China | CN¥149.90 Billion |
|
Charoen Pokphand Foods Public Company Limited
BK:CPF
|
Thailand | ฿618.83 Billion |
|
Allfunds Group Ltd
AS:ALLFG
|
Netherlands | €4.07 Billion |
|
Temenos Group AG
SW:TEMN
|
Switzerland | CHF1.77 Billion |
|
United Internet AG NA
XETRA:UTDI
|
Germany | €6.67 Billion |
|
SYSMEX CORP.UNSP.ADR 1/2
F:0YX0
|
Germany | €186.25 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down GlaxoSmithKline Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GlaxoSmithKline Pharmaceuticals Limited asset portfolio.
Liquidity & Leverage Metrics
GlaxoSmithKline Pharmaceuticals Limited Total Liabilities Ratios Explained
GlaxoSmithKline Pharmaceuticals Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
The table below shows the annual total liabilities of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs21.57 Billion ≈ $233.25 Million |
+21.24% |
| 2024-03-31 | Rs17.79 Billion ≈ $192.39 Million |
+12.22% |
| 2023-03-31 | Rs15.85 Billion ≈ $171.44 Million |
-19.54% |
| 2022-03-31 | Rs19.70 Billion ≈ $213.08 Million |
+22.06% |
| 2021-03-31 | Rs16.14 Billion ≈ $174.58 Million |
+22.76% |
| 2020-03-31 | Rs13.15 Billion ≈ $142.21 Million |
-25.77% |
| 2019-03-31 | Rs17.71 Billion ≈ $191.58 Million |
-6.28% |
| 2018-03-31 | Rs18.90 Billion ≈ $204.41 Million |
+89.59% |
| 2017-03-31 | Rs9.97 Billion ≈ $107.82 Million |
-26.15% |
| 2016-03-31 | Rs13.50 Billion ≈ $145.99 Million |
+72.99% |
| 2015-03-31 | Rs7.80 Billion ≈ $84.39 Million |
-31.54% |
| 2014-03-31 | Rs11.40 Billion ≈ $123.26 Million |
+5.38% |
| 2013-03-31 | Rs10.82 Billion ≈ $116.97 Million |
-4.29% |
| 2012-03-31 | Rs11.30 Billion ≈ $122.21 Million |
+31.57% |
| 2011-03-31 | Rs8.59 Billion ≈ $92.89 Million |
+20.68% |
| 2010-03-31 | Rs7.12 Billion ≈ $76.97 Million |
-4.47% |
| 2009-03-31 | Rs7.45 Billion ≈ $80.57 Million |
+13.69% |
| 2008-03-31 | Rs6.55 Billion ≈ $70.86 Million |
+12.14% |
| 2007-03-31 | Rs5.84 Billion ≈ $63.19 Million |
+3.83% |
| 2006-03-31 | Rs5.63 Billion ≈ $60.86 Million |
+14.80% |
| 2005-03-31 | Rs4.90 Billion ≈ $53.02 Million |
-- |
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more